PharmaBlock Sciences (Nanjing) Future Growth
Future criteria checks 4/6
PharmaBlock Sciences (Nanjing) is forecast to grow earnings and revenue by 25.7% and 16.1% per annum respectively. EPS is expected to grow by 25.6% per annum. Return on equity is forecast to be 9.5% in 3 years.
Key information
25.7%
Earnings growth rate
25.6%
EPS growth rate
Pharmaceuticals earnings growth | 18.6% |
Revenue growth rate | 16.1% |
Future return on equity | 9.5% |
Analyst coverage | Low |
Last updated | 18 Jun 2024 |
Recent future growth updates
Recent updates
We Think PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Taking Some Risk With Its Debt
Jul 31PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Increasing Its Dividend To CN¥0.31
Jun 12PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Apr 21PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Looks Just Right With A 25% Price Jump
Mar 07Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,707 | 391 | N/A | 399 | 2 |
12/31/2025 | 2,282 | 305 | N/A | 450 | 3 |
12/31/2024 | 1,974 | 239 | N/A | 527 | 3 |
3/31/2024 | 1,719 | 189 | 58 | 227 | N/A |
12/31/2023 | 1,725 | 197 | -69 | 247 | N/A |
9/30/2023 | 1,701 | 219 | -169 | 209 | N/A |
6/30/2023 | 1,704 | 275 | -133 | 320 | N/A |
3/31/2023 | 1,642 | 301 | -270 | 302 | N/A |
1/1/2023 | 1,595 | 314 | -311 | 247 | N/A |
9/30/2022 | 1,483 | 294 | -487 | 144 | N/A |
6/30/2022 | 1,315 | 258 | -556 | 88 | N/A |
3/31/2022 | 1,251 | 488 | -497 | 100 | N/A |
12/31/2021 | 1,202 | 487 | -268 | 238 | N/A |
9/30/2021 | 1,200 | 484 | -4 | 380 | N/A |
6/30/2021 | 1,184 | 478 | 112 | 342 | N/A |
3/31/2021 | 1,137 | 226 | 253 | 376 | N/A |
12/31/2020 | 1,022 | 184 | 196 | 272 | N/A |
9/30/2020 | 923 | 177 | 135 | 241 | N/A |
6/30/2020 | 831 | 170 | 90 | 222 | N/A |
3/31/2020 | 681 | 147 | 1 | 159 | N/A |
12/31/2019 | 662 | 152 | -46 | 127 | N/A |
9/30/2019 | 603 | 157 | 7 | 129 | N/A |
6/30/2019 | 558 | 149 | 25 | 116 | N/A |
3/31/2019 | 531 | 147 | 87 | 158 | N/A |
12/31/2018 | 478 | 133 | 112 | 160 | N/A |
9/30/2018 | 417 | 109 | 55 | 93 | N/A |
6/30/2018 | 362 | 89 | 61 | 106 | N/A |
3/31/2018 | 319 | 75 | 34 | 79 | N/A |
12/31/2017 | 273 | 67 | N/A | 55 | N/A |
9/30/2017 | 244 | 62 | N/A | 58 | N/A |
6/30/2017 | 219 | 44 | N/A | 29 | N/A |
3/31/2017 | 196 | 37 | N/A | 16 | N/A |
12/31/2016 | 188 | 36 | N/A | 23 | N/A |
9/30/2016 | 183 | 30 | N/A | 23 | N/A |
6/30/2016 | 177 | 31 | N/A | 27 | N/A |
3/31/2016 | 156 | 25 | N/A | 27 | N/A |
12/31/2015 | 136 | 20 | N/A | 28 | N/A |
12/31/2014 | 77 | 22 | N/A | 12 | N/A |
12/31/2013 | 59 | 18 | N/A | 18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300725's forecast earnings growth (25.7% per year) is above the savings rate (2.9%).
Earnings vs Market: 300725's earnings (25.7% per year) are forecast to grow faster than the CN market (22% per year).
High Growth Earnings: 300725's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300725's revenue (16.1% per year) is forecast to grow faster than the CN market (13.4% per year).
High Growth Revenue: 300725's revenue (16.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300725's Return on Equity is forecast to be low in 3 years time (9.5%).